"The US Food and Drug Administration (FDA) today approved asfotase alfa (Strensiq, Alexion Pharmaceuticals) as the first-ever therapy for patients who develop hypophosphatasia, a rare metabolic bone disorder, in childhood.
(Generic versions may still be available.)
Duranest Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Duranest (etidocaine hcl) Injection is a local anesthetic agent used for infiltration anesthesia, peripheral nerve blocks (e.g., brachial plexus, intercostal, retrobulbar, ulnar, inferior alveolar), and central neural block (i.e., lumbar or caudal epidural blocks). The brand name Duranest is discontinued, but generic versions may be available. Common side effects of Duranest include:
- rapid heart rate
- high or low blood pressure
- chills, or
As with all local anesthetic agents, the dose of Duranest Injection to be employed will depend upon the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the type of regional anesthetic technique, and the physical condition and tolerance of the individual patient. Duranest may interact with monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, phenothiazines, vasopressor drugs, and ergot-type oxytocic drugs. Tell your doctor all medications and supplements you use. During pregnancy, Duranest should be administered only if prescribed. Tell your doctor if you are pregnant before receiving treatment with Duranest. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Duranest (etidocaine hcl) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Duranest FDA Prescribing Information: Side Effects
Adverse experiences following the administration of etidocaine are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage, rapid absorption or unintended intravascular injection, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the party of the patient. Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported:
CNS manifestations are excitatory and/or depressant and may be characterized by light-headedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest.
Allergic reactions are characterized by cutaneous lesions, urticaria, edema or anaphylactoid reactions. Allergic reactions may occur as a result of sensitivity either to local anesthetic agents or to the methylparaben used as a preservative in multiple dose vials. The detection of sensitivity by skin testing is of doubtful value.
The incidences of adverse reactions associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration and the physical status of the patient.
In the practice of caudal or lumbar epidural block, occasional unintentional penetration of the subarachnoid space by the catheter may occur. Subsequent adverse effects may depend partially on the amount of drug administered subdurally. These may include spinal block of varying magnitude (including total spinal block), hypotension secondary to spinal block, loss of bladder and bowel control, and loss of perineal sensation and sexual function. Persistent motor, sensory and/or autonomic (sphincter control) deficit of some lower spinal segments with recovery (several months) or incomplete recovery have been reported in rare instances when caudal or lumbar epidural block has been attempted. Backache and headache have also been noted following use of these anesthetic procedures.
There have been reported cases of permanent injury to extraocular muscles requiring surgical repair following retrobulbar administration.
There have been rare reports of TRISMUS in patients who have received Duranest (etidocaine HCl) for dental anesthesia. Onset of symptoms occurs within hours or days upon resolution of blockade. No correlation has been demonstrated with dosage, administration technique or dental procedure. In most patients, symptoms resolved within days to weeks, although some reports have suggested that symptoms were present for many months. Symptomatic treatment with analgesics, moist heat and physiotherapy was helpful in some cases.
Read the entire FDA prescribing information for Duranest (Etidocaine HCl)
Additional Duranest Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.